S.Africa probes 3 drug giants over cancer meds pricing

June 13, 2017

South Africa's competition commission said Tuesday it had launched investigations into pharmaceutical giants Roche, Pfizer and Aspen for suspected overpricing of cancer drugs.

Swiss firm Roche and US company Pfizer are being probed over "excessive pricing" for breast and lung cancer medications respectively, while South Africa's Aspen is being investigated for overcharging over three different drugs.

"The commission has reason to believe that Roche and its USA-based biotechnology company, Genentech, have and continue to engage in excessive pricing, price discrimination... in the provision of breast cancer medicine in South Africa," it said in a statement.

It said it suspected Roche of engaging in anti-competitive conduct, prolonging its "hold on breast cancer drugs" and preventing cheaper generic alternatives from reaching the market.

Roche is also accused of charging different rates to private and public sector patients, possibly in breach of local competition laws.

The Swiss giant said it had not yet been notified of the investigation.

If notified, "we will be cooperating with the authorities and will provide all required information while responding to the potential allegation," said Roche.

The South African commission said it had "also initiated an investigation against pharmaceutical giant, Pfizer, for suspected excessive pricing of lung cancer medication in South Africa".

The commission is also investigating South Africa's Aspen for overcharging for three drugs used in the treatment of various strains of cancer including leukaemia, myeloma and ovarian cancer.

It suspects Aspen of "abuse of dominance by charging excessive prices in the provision of lifesaving cancer medicines in South Africa".

Aspen denied the allegations saying that pharmaceutical prices in the country are approved by the health ministry which establishes a universal fixed price for each drug.

"Aspen has not increased pricing of its products outside of this regulatory framework and has clearly demonstrated its commitment to providing quality medicines affordably over many years," it said in a statement.

"The supply of the oncology products in question is no exception."

Aspen is already under investigation in the European Union over suspicions that it abused its dominant market position in breach of EU antitrust rules.

The EU probe was announced last month.

Explore further: Roche buying Seragon in US for up to $1.7 billion

Related Stories

Roche buying Seragon in US for up to $1.7 billion

July 2, 2014
Roche Holding AG says its U.S.-based biotech company Genentech has agreed to acquire American biotechnology firm Seragon Pharmaceuticals, Inc. for up to $1.725 billion in cash and contingency payments.

Roche probed for not reporting side effects

October 23, 2012
(AP)—Europe's top drug regulator announced Tuesday it is taking action against pharmaceutical giant Roche for allegedly failing to properly report the side effects of 19 drugs being used by U.S. patients.

EU regulator: No more problems with Roche drugs

November 19, 2013
The European Medicines Agency says it has finished an investigation of the way pharmaceutical giant Roche reported side effects for 19 drugs in the U.S. and has found no new safety concerns.

FDA approves Roche's Avastin for ovarian cancer

November 14, 2014
Swiss drugmaker Roche said Friday that the Food and Drug Administration approved its drug Avastin as a treatment for ovarian cancer.

Roche breast cancer drug 'helps patients live longer': study

September 29, 2014
A drug developed by Swiss giant Roche to treat an aggressive form of breast cancer has been shown to extend patients' lives by almost 16 months, researchers said Sunday.

Roche warns of counterfeit cancer drug in US

February 14, 2012
(AP) -- The maker of the best-selling cancer drug Avastin is warning doctors and patients about counterfeit vials of the product distributed in the U.S.

Recommended for you

Data revealed under FOI shows benefits of multiple sclerosis drug currently blocked by regulators

August 17, 2017
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).

Opioids overused in migraine treatment, regardless of race, study finds

August 17, 2017
African-Americans are more likely to experience debilitating migraine headaches than whites, but a new study probing the issue found no evidence of racial disparities in treatment practices.

Finding better ways to reduce serious drug side effects

August 14, 2017
Many of the medicines we depend on to treat disease—and even to save our lives—pose potentially serious risks along with their benefits. Data from the U.S. Centers for Disease Control and Prevention indicate that about ...

Ultrasound-triggered liposomes for on-demand, local anesthesia

August 10, 2017
Researchers at Boston Children's Hospital have found a new way to non-invasively relieve pain at local sites in the body; such systems could one day improve pain management by replacing addictive opioids and short-lasting ...

Independent pharmacies and online coupons help patients save money on drugs

August 8, 2017
Uninsured patients or those with limited prescription drug coverage can save significant money by buying their drugs at independent pharmacies instead of big box, grocery or chain drug stores and by using discount coupons, ...

New study generates more accurate estimates of state opioid and heroin fatalities

August 7, 2017
Although opioid and heroin deaths have been rising dramatically in the U.S., the magnitude of the epidemic varies from state to state, as does the relative proportion of opioid vs heroin poisonings. Further complicating the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.